

TRACTATENBLAD

VAN HET

KONINKRIJK DER NEDERLANDEN

JAARGANG 2010 Nr. 80

A. TITEL

*Overeenkomst ter bestrijding van doping;
(met Bijlage)
Straatsburg, 16 november 1989*

B. TEKST

De Engelse en de Franse tekst van de Overeenkomst, met Bijlage, zijn geplaatst in *Trb.* 1991, 8.

Voor wijzigingen van de tekst van de Bijlage, zie de rubrieken J van *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44 en 244, *Trb.* 1998, 104, *Trb.* 2001, 98 en 185, *Trb.* 2003, 40, *Trb.* 2004, 194 en de rubrieken B van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83 en *Trb.* 2009, 24.

Voor enkele correcties zie *Trb.* 2008, 83 en *Trb.* 2009, 24.

De Commissie van Toezicht heeft tijdens haar 30^e vergadering op 19 november 2009, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, te Straatsburg een wijziging van de Bijlage aangenomen. De Engelse tekst van de wijziging luidt als volgt:

The 2010 prohibited list World Anti-Doping Code

Date of entry into force: 1 January 2010

All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S4.4 and S6.a, and *Prohibited Methods* M1, M2 and M3.

Substances and methods prohibited at all times (in- and out-of-competition)

Prohibited substances

SI. Anabolic agents

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)

a) Exogenous¹⁾ AAS, including:

1-androstendiol (5 α -androst-1-ene-3 β ,17 β -diol); 1-androstenedione (5 α -androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17 α -ethynyl-17 β -hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol); drostanolone; ethylestrenol (19-nor-17 α -pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17 β -hydroxy-17 α -methyl-5 α -androstano[2,3-c]-furan); gestrinone; 4-hydroxytestosterone (4,17 β -dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; methandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); methandriol; methasterone (2 α , 17 α -dimethyl-5 α -androstane-3-one-17 β -ol); methyl-dienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norbolone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17 β -hydroxy-5 α -androstano[3,2-c] pyrazole); quinbolone; stanozolol; stenbolone; 1-testosterone (17 β -hydroxy-5 α -androst-1-en-3-one); tetrahydrogestrinone (18 α -homo-pregna-4,9,11-trien-17 β -ol-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect(s).

b) Endogenous²⁾

AAS when administered exogenously:

androstenediol (androst-5-ene-3 β ,17 β -diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17 β -hydroxy-5 α -androst-3-one); prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers:

¹⁾ For purposes of this section:

“exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.

²⁾ “endogenous” refers to a substance which is capable of being produced by the body naturally.

5 α -androstane-3 α ,17 α -diol; 5 α -androstane-3 α ,17 β -diol; 5 α -androstane-3 β ,17 α -diol; 5 α -androstane-3 β ,17 β -diol; androst-4-ene-3 α ,17 α -diol; androst-4-ene-3 α ,17 β -diol; androst-4-ene-3 β ,17 α -diol; androst-5-ene-3 α ,17 α -diol; androst-5-ene-3 α ,17 β -diol; androst-5-ene-3 β ,17 α -diol; 4-androstenediol (androst-4-ene-3 β ,17 β -diol); 5-androstenedione (androst-5-ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; 3 α -hydroxy-5 α -androstan-17-one; 3 β -hydroxy-5 α -androstan-17-one; 19-norandrosterone; 19-noretiocholanolone.

2. Other Anabolic Agents, including but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.

S2. *Peptide hormones, growth factors and related substances*

The following substances and their releasing factors are prohibited:

1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoietin (dEPO), methoxy polyethylene glycol-epoetin beta (CERA), hematide];

2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males;

3. Insulins;

4. Corticotrophins;

5. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Fibroblast Growth Factors (FGFs), Vascular-Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching;

6. Platelet-derived preparations (e.g. Platelet Rich Plasma, “blood spinning”) administered by intramuscular route. Other routes of administration require a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions.

and other substances with similar chemical structure or similar biological effect(s).

S3. *Beta-2 agonists*

All beta-2 agonists (including both optical isomers where relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol by inhalation which require a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions.

The presence of salbutamol in urine in excess of 1000 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding* unless the *Athlete*

proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol.

S4. Hormone antagonists and modulators

The following classes are prohibited:

1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant.
4. Agents modifying myostatin function(s) including but not limited to: myostatin inhibitors.

S5. Diuretics and other masking agents

Masking agents are prohibited. They include:

Diuretics, probenecid, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol) and other substances with similar biological effect(s).

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).

A Therapeutic Use Exemption for diuretics and masking agents is not valid if an *Athlete's* urine contains such substance(s) in association with threshold or sub-threshold levels of an exogenous *Prohibited Substance(s)*.

Prohibited methods

M1. Enhancement of oxygen transfer

The following are prohibited:

1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.

b) Specified Stimulants (examples):

Adrenaline⁴⁾; cathine⁵⁾; ephedrine⁶⁾; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamphetamine; meclofenoxate; methylephedrine⁶⁾; methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine⁷⁾; selegiline; sibutramine; strychnine; tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s).

S7. *Narcotics*

The following narcotics are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. *Cannabinoids*

Natural or synthetic Δ 9-tetrahydrocannabinol (THC) and THC-like Cannabinoids (e.g. hashish, marijuana, HU-210) are prohibited.

S9. *Glucocorticosteroids*

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

In accordance with the International Standard for Therapeutic Use Exemptions, a declaration of *Use* must be completed by the *Athlete* for glucocorticosteroids administered by intraarticular, periarticular, peritendinous, epidural, intradermal and inhalation routes, except as noted below.

Topical preparations when used for auricular, buccal, dermatological (including iontophoresis/phonophoresis), gingival, nasal, ophthalmic and perianal disorders are not prohibited and require neither a Therapeutic Use Exemption nor a declaration of *Use*.

Substances prohibited in particular sports

P1. *Alcohol*

Alcohol (ethanol) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L.

⁴⁾ Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited.

⁵⁾ Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

⁶⁾ Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

⁷⁾ Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

- Aeronautic (FAI)
- Archery (FITA)
- Automobile (FIA)
- Karate (WKF)
- Modern Pentathlon (UIPM) for disciplines involving shooting
- Motorcycling (FIM)
- Ninepin and Tenpin Bowling (FIQ)
- Powerboating (UIM)

P2. Beta-blockers

Unless otherwise specified, beta-blockers are prohibited *In-Competition* only, in the following sports.

- Aeronautic (FAI)
- Archery (FITA) (also prohibited *Out-of-Competition*)
- Automobile (FIA)
- Billiards and Snooker (WCBS)
- Bobsleigh (FIBT)
- Boules (CMSB)
- Bridge (FMB)
- Curling (WCF)
- Golf (IGF)
- Gymnastics (FIG)
- Motorcycling (FIM)
- Modern Pentathlon (UIPM) for disciplines involving shooting
- Ninepin and Tenpin Bowling (FIQ)
- Powerboating (UIM)
- Sailing (ISAF) for match race helms only
- Shooting (ISSF, IPC) (also prohibited *Out-of-Competition*)
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/
halfpipe and snowboard halfpipe/big air
 - Wrestling (FILA)

Beta-blockers include, but are not limited to, the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

C. VERTALING

Zie *Trb.* 1991, 8.

D. PARLEMENT

Zie *Trb.* 1995, 114.

E. PARTIJGEGEVENS

Zie *Trb.* 1991, 8 en de rubrieken F en H van *Trb.* 1995, 114.

Partij	Onder- tekening	Ratificatie	Type*	In werking	Opzeg- ging	Buiten werking
Albanië	02-02-95	15-11-04	R	01-01-05		
Andorra	29-05-02	19-09-06	R	01-11-06		
Armenië	26-05-00	23-03-04	R	01-05-04		
Australië		05-10-94	T	01-12-94		
Azerbeidzjan	28-06-02	04-11-03	R	01-01-04		
Belarus	12-09-02	15-03-06	R	01-05-06		
België	16-11-89	30-11-01	R	01-01-02		
Bosnië en Herzegovina		29-12-94	T	01-02-95		
Bulgarije	24-03-92	01-06-92	R	01-08-92		
Canada		06-03-96	O	01-05-96		
Cyprus	20-06-91	02-02-94	R	01-04-94		
Denemarken		16-11-89	O	01-03-90		
Duitsland	27-05-92	28-04-94	R	01-06-94		
Estland	14-05-93	20-11-97	R	01-01-98		
Finland	16-11-89	26-04-90	R	01-06-90		
Frankrijk	16-11-89	21-01-91	R	01-03-91		
Georgië	02-07-01	22-05-03	R	01-07-03		
Griekenland	10-10-90	06-03-96	R	01-05-96		
Hongarije		29-01-90	O	01-03-90		
Ierland	25-06-92	29-01-03	R	01-03-03		
IJsland		25-03-91	O	01-05-91		
Italië	16-11-89	12-02-96	R	01-04-96		
Joegoslavië (< 25-06-1991)	10-07-91	10-07-91	R	01-09-91		
Kroatië		27-01-93	T	01-03-93		
Letland	23-01-97	23-01-97	R	01-03-97		

Partij	Onder- tekening	Ratificatie	Type*	In werking	Opzeg- ging	Buiten werking
Liechtenstein	16-11-89	22-05-00	R	01-07-00		
Litouwen	01-04-93	17-05-96	R	01-07-96		
Luxemburg	16-11-89	21-06-96	R	01-08-96		
Macedonië, Voormalige Joegoslavische Republiek		30-03-94	T	01-05-94		
Malta	09-09-94					
Moldavië	20-02-08	27-01-09	R	01-03-09		
Monaco	09-09-03	28-11-03	R	01-01-04		
Montenegro		14-06-06	VG	06-06-06		
Nederlanden, het Koninkrijk der – Nederland – Ned. Antillen – Aruba	04-12-90	11-04-95 06-11-08 –	R R	01-06-95 01-01-09 –		
Noorwegen		16-11-89	O	01-03-90		
Oekraïne	02-07-98	29-11-01	R	01-01-02		
Oostenrijk	10-05-90	10-07-91	R	01-09-91		
Polen	16-11-89	07-09-90	R	01-11-90		
Portugal	14-06-90	17-03-94	R	01-05-94		
Roemenië	16-06-94	07-12-98	R	01-02-99		
Russische Federatie		12-02-91	T	01-04-91		
San Marino	16-11-89	31-01-90	R	01-03-90		
Servië		28-02-01	T	01-04-01		
Slovenië		02-07-92	T	01-09-92		
Slowakije		06-05-93	O	01-07-93		
Spanje	16-11-89	20-05-92	R	01-07-92		
Tsjechië		28-04-95	O	01-06-95		
Tunesië		26-02-04	T	01-04-04		

Partij	Onder- tekening	Ratificatie	Type*	In werking	Opzeg- ging	Buiten werking
Turkije	16-11-89	22-11-93	R	01-01-94		
Verenigd Koninkrijk, het		16-11-89	O	01-03-90		
Zweden	16-11-89	29-06-90	R	01-08-90		
Zwitserland	16-11-89	05-11-92	R	01-01-93		
* O=Ondertekening zonder voorbehoud of vereiste van ratificatie, R= Bekrachtiging, aanvaarding, goedkeuring of kennisgeving, T=Toetreding, VG=Voortgezette gebondenheid, NB=Niet bekend						

Uitbreidingen

Frankrijk

Uitgebreid tot	In werking	Buiten werking
Bassas da India	01-03-1991	
Clipperton	01-03-1991	
Europa-eiland	01-03-1991	
Frans Guyana	01-03-1991	
Frans-Polynesië	01-03-1991	
Franse Zuidelijke en Zuidpoolgebieden	01-03-1991	
Glorioso-eilanden	01-03-1991	
Guadeloupe	01-03-1991	
Juan de Nova-eiland	01-03-1991	
Martinique	01-03-1991	
Mayotte	01-03-1991	
Nieuw Caledonië	01-03-1991	
Réunion	01-03-1991	
Sint Pierre en Miquelon	01-03-1991	
Tromelin	01-03-1991	
Wallis en Futuna	01-03-1991	

Verenigd Koninkrijk, het

Uitgebreid tot	In werking	Buiten werking
Man	01-10-1993	

Verklaringen, voorbehouden en bezwaren

Denemarken, 16 november 1989

Until further notice the signature of Denmark of this Convention does not engage Greenland and the Faroe Islands.

Griekenland, 7 juli 1994

The Government of the Hellenic Republic declares that the accession of the Former Yugoslav Republic of Macedonia to the Conventions of the Council of Europe to which the Hellenic Republic is a Contracting Party does not imply the recognition of the Former Yugoslav Republic of Macedonia by the Hellenic Republic.

Moldavië, 27 januari 2009

Until the full re-establishment of the territorial integrity of the Republic of Moldova, the provisions of the Convention will be applied only on the territory controlled effectively by the authorities of the Republic of Moldova.

G. INWERKINGTREDING

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, de rubrieken J van *Trb.* 1996, 284, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40 en *Trb.* 2004, 194, en de rubrieken G van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83 en *Trb.* 2009, 24.

De wijziging van de Bijlage van 19 november 2009 is op 1 januari 2010 in werking getreden.

J. VERWIJZINGEN

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 2004, 194, *Trb.* 2006, 33, *Trb.* 2008, 83 en *Trb.* 2009, 24.

Verbanden

Titel : Internationaal Verdrag tegen doping in de sport; Parijs,
19 oktober 2005
Laatste *Trb.* : *Trb.* 2010, 81

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van de Bijlage van 19 november 2009 zal zijn bekendgemaakt in Nederland en de Nederlandse Antillen op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de *zestiende* maart 2010.

De Minister van Buitenlandse Zaken,

M. J. M. VERHAGEN